Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation

May 15, 2023Journal of the American Heart Association

Sodium-Glucose Cotransporter-2 Inhibitors May Lower Stroke Risk in People with Diabetes and Irregular Heartbeat

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The stroke rate was 3.4% patient-years in users of sodium-glucose cotransporter-2 inhibitors (SGLT2i) compared to 4.3% in nonusers.

SGLT2i users experienced a 20% reduction in stroke risk compared to nonusers, with a hazard ratio of 0.80.
Patients with atrial fibrillation (AF) and diabetes are at an increased risk of stroke.
The study followed 9116 patients with AF and diabetes over 5 years.
No significant differences in baseline characteristics were found between SGLT2i users and nonusers.

AI simplified

Background Atrial fibrillation (AF) is associated with increasing risk of thromboembolic or ischemic stroke. The CHADS-VASc score is a well-established predictor of AF stroke. Patients with AF have an increased risk of stroke if they have diabetes. Use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) has been shown to be associated with favorable cardiovascular outcomes in patients with diabetes. It was unknown whether use of SGLT2i decreased stroke risk in patients with AF who have diabetes. Methods and Results A total of 9116 patients with AF and diabetes from the National Taiwan University historical cohort were longitudinally followed up for 5 years (January 2016-December 2020). The risk of stroke related to SGLT2i use was evaluated by Cox model, adjusting CHADS-VASc score in the propensity score-matched population with 474 SGLT2i users and 3235 nonusers. Adverse thromboembolic end points during follow-up were defined as ischemic stroke. The mean age was 73.2±10.5 years, and 61% of patients were men. There were no significant differences of baseline characteristics between users and nonusers of SGLT2i, including CHADS-VASc score in the propensity score-matched population. The stroke rate was 3.4% (95% CI, 2.8-4.2) patient-years in SGLT2i users and 4.3% (95% CI, 4.0-4.6) in nonusers (=0.021). SGLT2i users had a 20% reduction of stroke (hazard ratio, 0.80 [95% CI, 0.64-0.99];=0.043) after adjustment for the CHADS-VASc score. Conclusions Use of SGLT2i was associated with a lower stroke risk in patients with diabetes and AF, and it may be considered to escalate SGLT2i to the first-line treatment in patients with diabetes and AF. 2 2 2 2 2 2 2 2P P

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief